GlassScriptPhysician profile
Michael J Kehdi
NPI 1770929820
$2,774.92
in general payments reported to CMS, 2019-2025
21 companies · $223 in 2025
The $223 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,418 · 2020: $351 · 2021: $113 · 2022: $188 · 2023: $336 · 2024: $146 · 2025: $223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $705.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $704.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $716.83 | 2019-2025 | |
| Abbott Laboratories | $457.08 | 2019-2023 | Mitraclip |
| Janssen Pharmaceuticals, INC | $230.54 | 2019-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $221.03 | 2019-2025 | Camzyos, Eliquis |
| Astellas Pharma US INC | $164.98 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $163.55 | 2022-2025 | Lifevest |
| Boston Scientific Corporation | $149.25 | 2019-2022 | |
| Cardiovascular Systems INC. | $120.33 | 2019 | |
| Medtronic Vascular, INC. | $112.01 | 2019 | |
| Abiomed | $108.98 | 2020-2023 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.42 | 2024-2025 | Jardiance |
| Medtronic, INC. | $62.79 | 2021-2025 | Micra |
| Alnylam Pharmaceuticals INC. | $30.05 | 2025 | Onpattro |
| Actelion Pharmaceuticals US, INC. | $27.16 | 2023 | Uptravi, Opsumit |
| Lexicon Pharmaceuticals, INC. | $20.51 | 2023 | Inpefa |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $20.17 | 2025 | |
| Siemens Medical Solutions USA, INC. | $19.06 | 2023 | Corpath Imaging System |
| Amgen INC. | $18.40 | 2023 | Repatha |
| Astrazeneca Pharmaceuticals LP | $18.39 | 2023 | Brilinta |
| Bayer Healthcare Pharmaceuticals INC. | $17.61 | 2025 | |
| Kiniksa Pharmaceuticals, LTD. | $16.78 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kehdi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.